ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9
The present disclosure provides pharmaceutic compositions for oral delivery comprising an antisense oligonucleotide (e.g., CIVI 008) and an oral delivery agent such as 5-CNAC. In some aspects, the disclosure provides a capsule comprising a dry blend of CIVI 008 and 5-CNAC, and optionally a statin. L...
Saved in:
Main Authors | , , |
---|---|
Format | Patent |
Language | English Spanish |
Published |
18.08.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The present disclosure provides pharmaceutic compositions for oral delivery comprising an antisense oligonucleotide (e.g., CIVI 008) and an oral delivery agent such as 5-CNAC. In some aspects, the disclosure provides a capsule comprising a dry blend of CIVI 008 and 5-CNAC, and optionally a statin.
La presente divulgación proporciona composiciones farmacéuticas para la administración oral que comprenden un oligonucleótido antisentido (por ejemplo, CIVI 008) y un agente de administración oral tal como 5-CNAC. En algunos aspectos, la divulgación proporciona una cápsula que comprende una mezcla seca de CIVI 008 y 5-CNAC, y opcionalmente, una estatina. |
---|---|
Bibliography: | Application Number: MX20230006711 |